References
- MCDONAGH TA, METRA M, ADAMO M, GARDNER RS, BAUMBACH A, BOHM M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J. 2021;42(36):3599–3726.
- MCDONAGH TA, METRA M, ADAMO M, GARDNER RS, BAUMBACH A, BOHM M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J. 2023;44(37):3627–3639.
- PONIKOWSKI P, ANKER SD, ALHABIB KF, COWIE MR, FORCE TL, HU S, et al. Heart failure: preventing disease and death worldwide ESC Heart Fail. 2014;1(1):4–25.
- SAVARESE G, BECHER PM, LUND LH, SEFEROVIC P, ROSANO GMC, COATS AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology Cardiovasc Res. 2023;118(17):3272–3287.
- GROENEWEGEN A, RUTTEN FH, MOSTERD A, HOES AW. Epidemiology of heart failure Eur J Heart Fail. 2020;22(8):1342–1356.
- VIRANI SS, ALONSO A, BENJAMIN EJ, BITTENCOURT MS, CALLAWAY CW, CARSON AP, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association Circulation. 2020;141(9):e139–e596.
- BOZKURT B, COATS AJS, TSUTSUI H, ABDELHAMID CM, ADAMOPOULOS S, ALBERT N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure Eur J Heart Fail. 2021;23(3):352–380.
- LAM CSP, VOORS AA, DE BOER RA, SOLOMON SD, VAN VELDHUISEN DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies Eur Heart J. 2018;39(30):2780–2792.
- KOMAJDA M, LAM CS. Heart failure with preserved ejection fraction: a clinical dilemma Eur Heart J. 2014;35(16):1022–1032.
- DUNLAY SM, ROGER VL, REDFIELD MM. Epidemiology of heart failure with preserved ejection fraction Nat Rev Cardiol. 2017;14(10):591–602.
- PAULUS WJ, TSCHOPE C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 62(4):263–271.
- OWAN TE, HODGE DO, HERGES RM, JACOBSEN SJ, ROGER VL, REDFIELD MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 355(3):251–259.
- REDFIELD MM. Heart failure with preserved ejection fraction. N Engl J Med. 375(19):1868–1877.
- ZILE MR, BAICU CF, IKONOMIDIS JS, STROUD RE, NIETERT PJ, BRADSHAW AD, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 131(14):1247–1259.
- SHAH AM, SHAH SJ, ANAND IS, SWEITZER NK, O’MEARA E, HEITNER JF, et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail. 7(1):104–115.
- WESTERMANN D, KASNER M, STEENDIJK P, SPILLMANN F, RIAD A, WEITMANN K, et al. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation. 117(16):2051–2060.
- VAN HEEREBEEK L, BORBELY A, NIESSEN HW, BRONZWAER JG, VAN DER VELDEN J, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 113(16):1966–1973.
- WROBEL-NOWICKA K, WOJCIECHOWSKA C, JACHEC W, ZALEWSKA M, ROMUK E. The role of oxidative stress and inflammatory parameters in heart failure. Medicina (Kaunas). 60(5):760.
- MAISEL AS, DURAN JM, WETTERSTEN N. Natriuretic peptides in heart failure: Atrial and B-type natriuretic peptides. Heart Fail Clin. 14(1):13–25.
- TANASE DM, RADU S, AL SHURBAJI S, BAROI GL, FLORIDA COSTEA C, TURLIUC MD, et al. Natriuretic peptides in heart failure with preserved left ventricular ejection fraction: from molecular evidences to clinical implications. Int J Mol Sci. 20(11):2629.
- LI P, ZHAO H, ZHANG J, et al. Similarities and differences between HFmrEF and HFpEF. Front Cardiovasc Med. 8:678614.
- CLEMMENSEN I, PETERSEN LC, KLUFT C. Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur J Biochem. 156(2):327–333.
- KOPEVA KV, GRAKOVA EV, SHILOV SN, BEREZIKOVA EN, BOBYLEVA ET, TEPLYAKOV AT. Tetranectin as a potential novel prognostic biomarker in anthracycline-related cardiac dysfunction. Heart Vessels. 38(10):1256–1266.
- MCDONALD K, GLEZEVA N, COLLIER P, O’REILLY J, O’CONNELL E, TEA I, et al. Tetranectin, a potential novel diagnostic biomarker of heart failure, is expressed within the myocardium and associates with cardiac fibrosis. Sci Rep. 10(1):7507.
- BORLAUG BA, PAULUS WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 32(6):670–679.
- PIESKE B, TSCHOPE C, DE BOER RA, FRASER AG, ANKER SD, DONAL E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 40(40):3297–3317.
- IRAM S, RAHMAN S, CHOI I, KIM J. Insight into the function of tetranectin in human diseases: a review and prospects for tetranectin-targeted disease treatment. Heliyon. 10(1):e23512.
- HO JE, LYASS A, COURCHESNE P, CHEN G, LIU C, YIN X, et al. Protein biomarkers of cardiovascular disease and mortality in the community. J Am Heart Assoc. 7(14):e008108.
- WANG TJ, WOLLERT KC, LARSON MG, COGLIANESE E, MCCABE EL, CHENG S, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation. 126(13):1596–1604.
- GILSTRAP LG, WANG TJ. Biomarkers and cardiovascular risk assessment for primary prevention: an update. Clin Chem. 58(1):72–82.
- SAVARESE G, STOLFO D, SINAGRA G, LUND LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 19(2):100–116.
- VEDIN O, LAM CSP, KOH AS, BENSON L, TENG THK, TAY WT, et al. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circ Heart Fail. 10(6):e003875.